{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:35:58Z","timestamp":1762079758064,"version":"3.40.5"},"reference-count":207,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:sec>\n<jats:title>Background and Objective:<\/jats:title>\n<jats:p>Migraine is a neurovascular syndrome associated with unilateral, throbbing headache accompanied with nausea, vomiting and photo\/phonophobia. Several proteins are involved in the etiopathogenesis of migraine headache. The aim of the present review is to give an insight into the various target proteins involved in migraine headache pertaining to the development of a potential anti-migraine drug molecule. Proteins\/receptors such as serotonin (5-HT), Calcitonin Gene Related Peptide (CGRP), Transient Receptor Potential Vanilloid (TRPV1), cannabinoid, glutamate, opioid and histamine receptors play various roles in migraine. The nature of the proteins, their types, binding partner membrane proteins and the consequences of the reactions produced have been discussed. The studies conducted on animals and humans with the above mentioned target proteins\/receptors and the results obtained have also been reviewed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Calcitonin Gene Related Peptide (CGRP), a G protein coupled receptor (GPCR) significantly contributed to the progression of migraine. CGRP antagonist inhibits the release of CGRP from trigeminal neurons of trigeminal ganglion. Based on the study results, the present review suggests that the inhibition of CGRP receptor might be a successful way to treat migraine headache. Currently, researchers across the world are focussing their attention towards the development of novel molecules to treat migraine headache by targeting CGRP receptor which can be attributed to its specificity among the several proteins involved in migraine.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467213999200824124532","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T05:12:12Z","timestamp":1598332332000},"page":"11-26","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug"],"prefix":"10.1016","volume":"14","author":[{"given":"Krishna P.","family":"Naduchamy","sequence":"first","affiliation":[{"name":"Immunology Laboratory, Department of Pharmacy, Annamalai University, Annamalai nagar-608002, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varadarajan","family":"Parthasarathy","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Department of Pharmacy, Annamalai University, Annamalai nagar-608002, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1526-4610.2005.4501001.x","volume":"45","author":"Lipton R.B.","year":"2005","unstructured":"Lipton R.B.; Bigal M.E.; Migraine: epidemiology, impact, and risk factors for progression. Headache 2005,45(Suppl. 1),S3-S13","journal-title":"Headache"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1526-4610.2012.02265.x","volume":"53","author":"Lipton R.B.","year":"2013","unstructured":"Lipton R.B.; Serrano D.; Holland S.; Fanning K.M.; Reed M.L.; Buse D.C.; Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013,53(1),81-92","journal-title":"Headache"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrn1102","volume":"4","author":"Pietrobon D.","year":"2003","unstructured":"Pietrobon D.; Striessnig J.; Neurobiology of migraine. Nat Rev Neurosci 2003,4(5),386-398","journal-title":"Nat Rev Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2006.00309.x","volume":"46","author":"Martin V.T.","year":"2006","unstructured":"Martin V.T.; Behbehani M.; Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I. Headache 2006,46(1),3-23","journal-title":"Headache"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.295.15.1824","volume":"295","author":"Brandes J.L.","year":"2006","unstructured":"Brandes J.L.; The influence of estrogen on migraine: a systematic review. JAMA 2006,295(15),1824-1830","journal-title":"JAMA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1172\/JCI5347","volume":"103","author":"Chen Z.","year":"1999","unstructured":"Chen Z.; Yuhanna I.S.; Galcheva-Gargova Z.; Karas R.H.; Mendelsohn M.E.; Shaul P.W.; Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999,103(3),401-406","journal-title":"J Clin Invest"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijsu.2015.07.710","volume":"22","author":"Arumugam M.","year":"2015","unstructured":"Arumugam M.; Parthasarathy V.; Increased incidence of migraine in women correlates with obstetrics and gynaecological surgical procedures. Int J Surg 2015,22,105-109","journal-title":"Int J Surg"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00002508-200307000-00009","volume":"19","author":"Spierings E.L.H.","year":"2003","unstructured":"Spierings E.L.H.; Pathogenesis of the migraine attack. Clin J Pain 2003,19(4),255-262","journal-title":"Clin J Pain"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0304-3959(93)90057-V","volume":"53","author":"Rasmussen B.K.","year":"1993","unstructured":"Rasmussen B.K.; Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993,53(1),65-72","journal-title":"Pain"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1526-4610.2006.00322.x","volume":"46","author":"Villeneuve P.J.","year":"2006","unstructured":"Villeneuve P.J.; Szyszkowicz M.; Stieb D.; Bourque D.A.; Weather and emergency room visits for migraine headaches in Ottawa, Canada. Headache 2006,46(1),64-72","journal-title":"Headache"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1046\/j.1468-2982.2003.00544.x","volume":"23","author":"Zivadinov R.","year":"2003","unstructured":"Zivadinov R.; Willheim K.; Sepic-Grahovac D.; Jurjevic A.; Bucuk M.; Brnabic-Razmilic O.; Relja G.; Zorzon M.; Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia 2003,23(5),336-343","journal-title":"Cephalalgia"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.0306147101","volume":"101","author":"Levy D.","year":"2004","unstructured":"Levy D.; Jakubowski M.; Burstein R.; Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B\/1D receptor agonists. Proc Natl Acad Sci USA 2004,101(12),4274-4279","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0021-9258(18)57137-4","volume":"176","author":"Rapport M.M.","year":"1948","unstructured":"Rapport M.M.; Green A.A.; Page I.H.; Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948,176(3),1243-1251","journal-title":"J Biol Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0021-9258(19)51208-X","volume":"180","author":"Rapport M.M.","year":"1949","unstructured":"Rapport M.M.; Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle. J Biol Chem 1949,180(3),961-969","journal-title":"J Biol Chem"},{"key":"ref=15","first-page":"219","volume":"50","author":"Bouchelet I.","year":"1996","unstructured":"Bouchelet I.; Cohen Z.; Case B.; S\u00e9gu\u00e9la P.; Hamel E.; Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996,50(2),219-223","journal-title":"Mol Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0304-3940(98)00680-6","volume":"254","author":"Bonaventure P.","year":"1998","unstructured":"Bonaventure P.; Langlois X.; Leysen J.E.; Co-localization of 5-HT1B- and 5-HT receptor mRNA in serotonergic cell bodies in guinea pig dorsal raph\u00e9 nucleus: a double labeling in situ hybridization histochemistry study. Neurosci Lett 1998,254(2),113-116","journal-title":"Neurosci Lett"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.91.9.3666","volume":"91","author":"Rebeck G.W.","year":"1994","unstructured":"Rebeck G.W.; Maynard K.I.; Hyman B.T.; Moskowitz M.A.; Selective 5-HT alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994,91(9),3666-3669","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","volume":"33","author":"Bruinvels A.T.","year":"1994","unstructured":"Bruinvels A.T.; Landwehrmeyer B.; Gustafson E.L.; Durkin M.M.; Mengod G.; Branchek T.A.; Hoyer D.; Palacios J.M.; Localization of 5-HT1B, 5-HT alpha, 5-HT1E and 5-HT receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994,33(3-4),367-386","journal-title":"Neuropharmacology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00168556","volume":"352","author":"Waeber C.","year":"1995","unstructured":"Waeber C.; Moskowitz M.A.; [3H]sumatriptan labels both 5-HT and 5-HT receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995,352(3),263-275","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjp.0702773","volume":"128","author":"Nilsson T.","year":"1999","unstructured":"Nilsson T.; Longmore J.; Shaw D.; Olesen I.J.; Edvinsson L.; Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999,128(6),1133-1140","journal-title":"Br J Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1468-2982.1999.019004248.x","volume":"19","author":"Goldstein D.J.","year":"1999","unstructured":"Goldstein D.J.; Offen W.W.; Moster M.B.; Efficacy definitions for migraine studies. Cephalalgia 1999,19(4),248-249","journal-title":"Cephalalgia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"Tepper S.J.","year":"2002","unstructured":"Tepper S.J.; Rapoport A.M.; Sheftell F.D.; Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch Neurol 2002,59(7),1084-1088","journal-title":"Arch Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0165-0173(00)00048-5","volume":"35","author":"Mitsikostas D.D.","year":"2001","unstructured":"Mitsikostas D.D.; Sanchez del Rio M.; Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Brain Res Rev 2001,35(1),20-35","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMp048016","volume":"350","author":"Durham P.L.","year":"2004","unstructured":"Durham P.L.; CGRP-receptor antagonists--a fresh approach to migraine therapy? N Engl J Med 2004,350(11),1073-1075","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1468-2982.2003.00719.x","volume":"24","author":"Edvinsson L.","year":"2004","unstructured":"Edvinsson L.; Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004,24(8),611-622","journal-title":"Cephalalgia"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","volume":"8","author":"Johnson K.W.","year":"1997","unstructured":"Johnson K.W.; Schaus J.M.; Durkin M.M.; Audia J.E.; Kaldor S.W.; Flaugh M.E.; Adham N.; Zgombick J.M.; Cohen. M.L.; Branchek. T.A.; Phebus. L.A. 5-HT receptor agonist inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997,8,2237-2240","journal-title":"Neuroreport"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1021\/jm0155190","volume":"44","author":"Xu Y.C.","year":"2001","unstructured":"Xu Y.C.; Johnson K.W.; Phebus L.A.; Cohen M.; Nelson D.L.; Schenck K.; Walker C.D.; Fritz J.E.; Kaldor S.W.; LeTourneau M.E.; Murff R.E.; Zgombick J.M.; Calligaro D.O.; Audia J.E.; Schaus J.M.; N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy. J Med Chem 2001,44(24),4031-4034","journal-title":"J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1021\/jm030020m","volume":"46","year":"2003","unstructured":"Filla. S.A.; Mathes. B.M.; Johnson. K.W.; Phebus. L.A.; Cohen. M.L.; Nelson. D.L.; Zgombick. J.M.; Erickson. J.A.; Schenck. K.W.; Wainscott. D.B.; Branchek. T.A.; Schaus. J. M. Novel potent 5-HT receptor agonist: Structure-Activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrole [3,2-b] pyridine-5-yl] amides. J Med Chem 2003,46(14),3060-3071","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s002109900045","volume":"360","year":"1999","unstructured":"Activation and desensitization by cyclic antidepressant drugs of \u03b12-autoreceptors, \u03b12-heteroreceptors and 5- HT1A-autoreceptors regulating monoamine synthesis in the rat brain in vivo. Naunyn-Schmiedeberg\u2019s Arch Pharmacol Susana Esteban, S.; Llad\u00f3, J.; Sastre-Coll, A.; Garc\u00eda-Sevilla, J.A1999,360(2),135-143","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1129-2377-14-S1-P77","volume":"14","author":"Hunfeld A.","year":"2013","unstructured":"Hunfeld A.; Segelcke D.; Andriske M.; Paris F.; Zhu. X.; L\u00fcbbert. H. Investigation of 5-HT2B receptor induced dural plasma protein extravasation in a mouse migraine model. J Headache Pain 2013,14(Suppl. 1),77","journal-title":"J Headache Pain"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0028-3908(89)90040-3","volume":"28","author":"Giordano J.","year":"1989","unstructured":"Giordano J.; Dyche J.; Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacology 1989,28(4),423-427","journal-title":"Neuropharmacology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0014-2999(89)90137-4","volume":"170","author":"Giordano J.","year":"1989","unstructured":"Giordano J.; Rogers L.V.; Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989,170(1-2),83-86","journal-title":"Eur J Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00614305","volume":"30","author":"Orwin J.M.","year":"1986","unstructured":"Orwin J.M.; Fozard J.R.; Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors. Eur J Clin Pharmacol 1986,30(2),209-212","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1468-2982.2000.00069.x","volume":"20","author":"Pascual J.","year":"2000","unstructured":"Pascual J.; Vega P.; Diener H-C.; Allen C.; Vrijens F.; Patel K.; Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia Rizatriptan-Zolmitriptan Study Group2000,20(5),455-461","journal-title":"Cephalalgia"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.vph.2005.07.001","volume":"43","author":"Arulmozhi D.K.","year":"2005","unstructured":"Arulmozhi D.K.; Veeranjaneyulu A.; Bodhankar S.L.; Migraine: current concepts and emerging therapies. Vascul Pharmacol 2005,43(3),176-187","journal-title":"Vascul Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sigm.2005.10.002","volume":"3","author":"Sabuda J.T.","year":"2005","unstructured":"Sabuda J.T.; Innovative approach to migraine headache and other neurologic conditions. Semin in Integr Med 2005,3(3),93-100","journal-title":"Semin in Integr Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s001340050894","volume":"25","author":"Granier I.","year":"1999","unstructured":"Granier I.; Garcia E.; Geissler A.; Boespflug M.D.; Durand-Gasselin J.; Postpartum cerebral angiopathy associated with the administration of sumatriptan and dihydroergotamine--a case report. Intensive Care Med 1999,25(5),532-534","journal-title":"Intensive Care Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000085061","volume":"53","author":"Diener H-C.","year":"2005","unstructured":"Diener H-C.; Gendolla A.; Gebert I.; Beneke M.; Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol 2005,53(Suppl. 1),41-48","journal-title":"Eur Neurol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0165-6147(00)01555-8","volume":"21","author":"Juaneda C.","year":"2000","unstructured":"Juaneda C.; Dumont Y.; Quirion R.; The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 2000,21(11),432-438","journal-title":"Trends Pharmacol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/pr.54.2.233","volume":"54","author":"Poyner D.R.","year":"2002","unstructured":"Poyner D.R.; Sexton P.M.; Marshall I.; Smith D.M.; Quirion R.; Born W.; Muff R.; Fischer J.A.; Foord S.M.; International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002,54(2),233-246","journal-title":"Pharmacol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"Amara S.G.","year":"1982","unstructured":"Amara S.G.; Jonas V.; Rosenfeld M.G.; Ong E.S.; Evans R.M.; Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982,298(5871),240-244","journal-title":"Nature"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1046\/j.1468-2982.1996.1605310.x","volume":"16","author":"Jansen-Olesen I.","year":"1996","unstructured":"Jansen-Olesen I.; Mortensen A.; Edvinsson L.; Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996,16(5),310-316","journal-title":"Cephalalgia"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"Rosenfeld M.G.","year":"1983","unstructured":"Rosenfeld M.G.; Mermod J.J.; Amara S.G.; Swanson L.W.; Sawchenko P.E.; Rivier J.; Vale W.W.; Evans R.M.; Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983,304(5922),129-135","journal-title":"Nature"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.1992.tb22759.x","volume":"657","author":"Quirion R.","year":"1992","unstructured":"Quirion R.; Van Rossum D.; Dumont Y.; St-Pierre S.; Fournier A.; Characterization of CGRP1 and CGRP2 receptor subtypes. Ann N Y Acad Sci 1992,657,88-105","journal-title":"Ann N Y Acad Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0149-7634(96)00023-1","volume":"21","author":"van Rossum D.","year":"1997","unstructured":"van Rossum D.; Hanisch U.K.; Quirion R.; Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997,21(5),649-678","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0165-6147(00)91555-4","volume":"22","author":"Poyner D.","year":"2001","unstructured":"Poyner D.; Marshall I.; CGRP receptors: beyond the CGRP(1)-CGRP(2) subdivision? Trends Pharmacol Sci 2001,22(5),223","journal-title":"Trends Pharmacol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1210\/edrv-17-5-533","volume":"17","author":"Wimalawansa S.J.","year":"1996","unstructured":"Wimalawansa S.J.; Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996,17(5),533-585","journal-title":"Endocr Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1749-6632.1992.tb22766.x","volume":"657","author":"Sternini C.","year":"1992","unstructured":"Sternini C.; Enteric and visceral afferent CGRP neurons. Targets of innervation and differential expression patterns. Ann N Y Acad Sci 1992,657,170-186","journal-title":"Ann N Y Acad Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/30666","volume":"393","author":"McLatchie L.M.","year":"1998","unstructured":"McLatchie L.M.; Fraser N.J.; Main M.J.; Wise A.; Brown J.; Thompson N.; Solari R.; Lee M.G.; Foord S.M.; RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998,393(6683),333-339","journal-title":"Nature"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1042\/bst0300451","volume":"30","author":"Conner A.C.","year":"2002","unstructured":"Conner A.C.; Hay D.L.; Howitt S.G.; Kilk K.; Langel U.; Wheatley M.; Smith D.M.; Poyner D.R.; Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans 2002,30(4),451-455","journal-title":"Biochem Soc Trans"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/molehr\/6.9.811","volume":"6","author":"Nikitenko L.L.","year":"2000","unstructured":"Nikitenko L.L.; MacKenzie I.Z.; Rees M.C.P.; Bicknell R.; Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000,6(9),811-819","journal-title":"Mol Hum Reprod"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/sj.bjp.0703655","volume":"131","author":"Powell K.J.","year":"2000","unstructured":"Powell K.J.; Ma W.; Sutak M.; Doods H.; Quirion R.; Jhamandas K.; Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 2000,131(5),875-884","journal-title":"Br J Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0006-8993(87)90074-6","volume":"403","author":"Oku R.","year":"1987","unstructured":"Oku R.; Satoh M.; Fujii N.; Otaka A.; Yajima H.; Takagi H.; Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 1987,403(2),350-354","journal-title":"Brain Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"24994","DOI":"10.1074\/jbc.M211379200","volume":"278","author":"Rossi S.G.","year":"2003","unstructured":"Rossi S.G.; Dickerson I.M.; Rotundo R.L.; Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem 2003,278(27),24994-25000","journal-title":"J Biol Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1468-2982.1997.1703166.x","volume":"17","author":"Ottosson A.","year":"1997","unstructured":"Ottosson A.; Edvinsson L.; Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997,17(3),166-174","journal-title":"Cephalalgia"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0028-3908(02)00008-4","volume":"42","author":"Moreno M.J.","year":"2002","unstructured":"Moreno M.J.; Abounader R.; H\u00e9bert E.; Doods H.; Hamel E.; Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002,42(4),568-576","journal-title":"Neuropharmacology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1021\/jm0490641","volume":"48","author":"Rudolf K.","year":"2005","unstructured":"Rudolf K.; Eberlein W.; Engel W.; Pieper H.; Entzeroth M.; Hallermayer G.; Doods H.; Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 2005,48(19),5921-5931","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.nurt.2010.02.004","volume":"7","author":"Edvinsson L.","year":"2010","unstructured":"Edvinsson L.; Ho T.W.; CGRP receptor antagonism and migraine Neuro ther 2010,7,164-175","journal-title":"Neuro ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"Connor K.M.","year":"2009","unstructured":"Connor K.M.; Shapiro R.E.; Diener H.C.; Lucas S.; Kost J.; Fan X.; Fei K.; Assaid C.; Lines C.; Ho T.W.; Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009,73(12),970-977","journal-title":"Neurology"},{"key":"ref=60","unstructured":""},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1748-1716.1962.tb02477.x","volume":"56","author":"Carlsson A.","year":"1962","unstructured":"Carlsson A.; Falck B.; Hillarp N.A.; Cellular localization of brain monoamines. Acta Physiol Scand Suppl 1962,56(196),1-28","journal-title":"Acta Physiol Scand Suppl"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.tins.2007.03.004","volume":"30","author":"Bj\u00f6rklund A.","year":"2007","unstructured":"Bj\u00f6rklund A.; Dunnett S.B.; Fifty years of dopamine research. Trends Neurosci 2007,30(5),185-187","journal-title":"Trends Neurosci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0006-8993(79)90391-3","volume":"169","author":"Reisine T.D.","year":"1979","unstructured":"Reisine T.D.; Nagy J.I.; Fibiger H.C.; Yamamura H.I.; Localization of dopamine receptors in rat brain. Brain Res 1979,169(1),209-214","journal-title":"Brain Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1212\/WNL.40.11.1660","volume":"40","author":"De Keyser J.","year":"1990","unstructured":"De Keyser J.; Herregodts P.; Ebinger G.; The mesoneocortical dopamine neuron system. Neurology a1990,40(11),1660-1662","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.21077","volume":"61","author":"Bergerot A.","year":"2007","unstructured":"Bergerot A.; Storer R.J.; Goadsby P.J.; Dopamine inhibits trigeminovascular transmission in the rat. Ann Neurol 2007,61(3),251-262","journal-title":"Ann Neurol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.mehy.2005.09.045","volume":"66","author":"Chen S.C.","year":"2006","unstructured":"Chen S.C.; Epilepsy and migraine: The dopamine hypotheses. Med Hypotheses 2006,66(3),466-472","journal-title":"Med Hypotheses"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1526-4610.1994.hed3409536.x","volume":"34","author":"Del Bene E.","year":"1994","unstructured":"Del Bene E.; Poggioni M.; De Tommasi F.; Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 1994,34(9),536-538","journal-title":"Headache"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1468-2982.1998.1804174.x","volume":"18","author":"Mascia A.","year":"1998","unstructured":"Mascia A.; Afra J.; Schoenen J.; Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia 1998,18(4),174-182","journal-title":"Cephalalgia"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1212\/WNL.51.3.781","volume":"51","author":"Del Zompo M.","year":"1998","unstructured":"Del Zompo M.; Cherchi A.; Palmas M.A.; Ponti M.; Bocchetta A.; Gessa G.L.; Piccardi M.P.; Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 1998,51(3),781-786","journal-title":"Neurology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1468-1331.2010.02988.x","volume":"17","author":"Garc\u00eda-Mart\u00edn E.","year":"2010","unstructured":"Garc\u00eda-Mart\u00edn E.; Mart\u00ednez C.; Serrador M.; Alonso-Navarro H.; Navacerrada F.; Ag\u00fandez J.A.G.; Jim\u00e9nez-Jim\u00e9nez F.J.; Dopamine receptor 3 (DRD3) polymorphism and risk for migraine. Eur J Neurol 2010,17(9),1220-1223","journal-title":"Eur J Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.2000.00001.x","volume":"20","author":"Barbanti P.","year":"2000","unstructured":"Barbanti P.; Fabbrini G.; Ricci A.; Pascali M.P.; Bronzetti E.; Amenta F.; Lenzi G.L.; Cerbo R.; Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia 2000,20(1),15-19","journal-title":"Cephalalgia"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1046\/j.1526-4610.2002.02105.x","volume":"42","year":"2002","unstructured":"Greame shepherd.; Lea, R.A.; Colin Hutchins.; Jordan, K.L.; Brimage, P.J.; Griffiths, L.R. Dopamine receptor genes and migraine with and without aura: An association study. Headache 2002,42,346-351","journal-title":"Headache"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s100720300005","volume":"23","author":"Mochi M.","year":"2003","unstructured":"Mochi M.; Cevoli S.; Cortelli P.; Pierangeli G.S.; Soriani C.; Scapoli. P.; Montagna. A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-betahydroxylase genes. Neurol Sci 2003,23(6),301-305","journal-title":"Neurol Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/ajem.2002.30007","volume":"20","author":"Richman P.B.","year":"2002","unstructured":"Richman P.B.; Allegra J.; Eskin B.; Doran J.; Reischel U.; Kaiafas C.; Nashed A.H.; A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med 2002,20(1),39-42","journal-title":"Am J Emerg Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0735-6757(99)90096-7","volume":"17","author":"Richman P.B.","year":"1999","unstructured":"Richman P.B.; Reischel U.; Ostrow A.; Irving C.; Ritter A.; Allegra J.; Eskin B.; Szucs P.; Nashed A.H.; Droperidol for acute migraine headache. Am J Emerg Med 1999,17(4),398-400","journal-title":"Am J Emerg Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1096\/fasebj.9.7.7737460","volume":"9","author":"Knapp R.J.","year":"1995","unstructured":"Knapp R.J.; Malatynska E.; Collins N.; Fang L.; Wang J.Y.; Hruby V.J.; Roeske W.R.; Yamamura H.I.; Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995,9(7),516-525","journal-title":"FASEB J"},{"key":"ref=77","first-page":"469","author":"Tripathi K.D.","year":"2013","unstructured":"Tripathi K.D.;  Essentials of Medical Pharmacology, 7th ed 2013,469-485","journal-title":"Essentials of Medical Pharmacology, 7th ed"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/acn3.66","volume":"1","author":"Nascimento T.D.","year":"2014","unstructured":"Nascimento T.D.; DosSantos M.F.; Sarah Lucas.; Holsbeeck, H.V.; DeBoer, M.; Maslowski, E.; Tiffany Love.; Martikainen, I.K.; Koeppe, R.A.; Smith, Y.R.; Jon-kar Zubeita.; DaSilva, A.F. \u00b5-Opioid activation in the midbrain during migraine allodynia-brief report II. Ann Clin Transl Neurol 2014,1(6),445-450","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1100\/tsw.2007.230","volume":"7","author":"Hutchinson M.R.","year":"2007","unstructured":"Hutchinson M.R.; Bland S.T.; Johnson K.W.; Rice K.C.; Maier S.F.; Watkins L.R.; Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007,7,98-111","journal-title":"ScientificWorldJournal"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/bph.12591","volume":"171","author":"Pradhan A.A.","year":"2014","unstructured":"Pradhan A.A.; Smith M.L.; Zyuzin J.; Charles A.; \u03b4-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. Br J Pharmacol 2014,171(9),2375-2384","journal-title":"Br J Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/BF02042625","volume":"5","author":"Bussone G.","year":"1984","unstructured":"Bussone G.; Boiardi A.; La Mantia L.; Frediani F.; Martini A.; Di Giulio A.M.; Panerai A.E.; Neuroendocrinological study of opioid and serotoninergic systems in migraine patients. Ital J Neurol Sci 1984,5(4),413-416","journal-title":"Ital J Neurol Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI119506","volume":"100","author":"Cabot P.J.","year":"1997","unstructured":"Cabot P.J.; Carter L.; Gaiddon C.; Zhang Q.; Sch\u00e4fer M.; Loeffler J.P.; Stein C.; Immune cell-derived \u03b2-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest 1997,100(1),142-148","journal-title":"J Clin Invest"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1073\/pnas.91.10.4219","volume":"91","author":"Sch\u00e4fer M.","year":"1994","unstructured":"Sch\u00e4fer M.; Carter L.; Stein C.; Interleukin 1 \u03b2 and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 1994,91(10),4219-4223","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1526-4610.1992.hed3207348.x","volume":"32","author":"Nicolodi M.","year":"1992","unstructured":"Nicolodi M.; Sicuteri F.; Chronic naloxone administration, a potential treatment for migraine, enhances morphine-induced miosis. Headache 1992,32(7),348-352","journal-title":"Headache"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","volume":"86","author":"Gaoni Y.","year":"1964","unstructured":"Gaoni Y.; Mechoulam R.; Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964,86,1646-1647","journal-title":"J Am Chem Soc"},{"key":"ref=86","first-page":"75","volume":"38","author":"Razdan R.K.","year":"1986","unstructured":"Razdan R.K.; Structure-activity relationships in cannabinoids. Pharmacol Rev 1986,38(2),75-149","journal-title":"Pharmacol Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"Herkenham M.","year":"1990","unstructured":"Herkenham M.; Lynn A.B.; Little M.D.; Johnson M.R.; Melvin L.S.; de Costa B.R.; Rice K.C.; Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990,87(5),1932-1936","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"Herkenham M.","year":"1991","unstructured":"Herkenham M.; Lynn A.B.; Johnson M.R.; Melvin L.S.; de Costa B.R.; Rice K.C.; Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991,11(2),563-583","journal-title":"J Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","volume":"83","author":"Tsou K.","year":"1998","unstructured":"Tsou K.; Brown S.; Sa\u00f1udo-Pe\u00f1a M.C.; Mackie K.; Walker J.M.; Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998,83(2),393-411","journal-title":"Neuroscience"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"Howlett A.C.","year":"2002","unstructured":"Howlett A.C.; Barth F.; Bonner T.I.; Cabral G.; Casellas P.; Devane W.A.; Felder C.C.; Herkenham M.; Mackie K.; Martin B.R.; Mechoulam R.; Pertwee R.G.; International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002,54(2),161-202","journal-title":"Pharmacol Rev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0005-2760(98)00042-3","volume":"1392","author":"Di Marzo V.","year":"1998","unstructured":"Di Marzo V.; \u2018Endocannabinoids\u2019 and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998,1392(2-3),153-175","journal-title":"Biochim Biophys Acta"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1385\/NMM:7:1-2:037","volume":"7","author":"van der Stelt M.","year":"2005","unstructured":"van der Stelt M.; Di Marzo V.; Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 2005,7(1-2),37-50","journal-title":"Neuromolecular Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","volume":"13","author":"Maresz K.","year":"2007","unstructured":"Maresz K.; Pryce G.; Ponomarev E.D.; Marsicano G.; Croxford J.L.; Shriver L.P.; Ledent C.; Cheng X.; Carrier E.J.; Mann M.K.; Giovannoni G.; Pertwee R.G.; Yamamura T.; Buckley N.E.; Hillard C.J.; Lutz B.; Baker D.; Dittel B.N.; Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007,13(4),492-497","journal-title":"Nat Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02791072.1988.10524365","volume":"20","author":"Wallace J.M.","year":"1988","unstructured":"Wallace J.M.; Tashkin D.P.; Oishi J.S.; Barbers R.G.; Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. J Psychoactive Drugs 1988,20(1),9-14","journal-title":"J Psychoactive Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1073\/pnas.90.16.7656","volume":"90","author":"Felder C.C.","year":"1993","unstructured":"Felder C.C.; Briley E.M.; Axelrod J.; Simpson J.T.; Mackie K.; Devane W.A.; Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993,90(16),7656-7660","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=96","first-page":"443","volume":"48","author":"Felder C.C.","year":"1995","unstructured":"Felder C.C.; Joyce K.E.; Briley E.M.; Mansouri J.; Mackie K.; Blond O.; Lai Y.; Ma A.L.; Mitchell R.L.; Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995,48(3),443-450","journal-title":"Mol Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1152\/jn.1997.78.1.43","volume":"78","author":"Twitchell W.","year":"1997","unstructured":"Twitchell W.; Brown S.; Mackie K.; Cannabinoids inhibit N- and P\/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997,78(1),43-50","journal-title":"J Neurophysiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1523\/JNEUROSCI.15-10-06552.1995","volume":"15","author":"Mackie K.","year":"1995","unstructured":"Mackie K.; Lai Y.; Westenbroek R.; Mitchell R.; Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995,15(10),6552-6561","journal-title":"J Neurosci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/0091-3057(93)90230-Q","volume":"46","author":"Crawley J.N.","year":"1993","unstructured":"Crawley J.N.; Corwin R.L.; Robinson J.K.; Felder C.C.; Devane W.A.; Axelrod J.; Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993,46(4),967-972","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=100","first-page":"219","volume":"270","author":"Smith P.B.","year":"1994","unstructured":"Smith P.B.; Compton D.R.; Welch S.P.; Razdan R.K.; Mechoulam R.; Martin B.R.; The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994,270(1),219-227","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.106.106971","volume":"320","author":"Akerman S.","year":"2007","unstructured":"Akerman S.; Holland P.R.; Goadsby P.J.; Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 2007,320(1),64-71","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neulet.2009.06.021","volume":"461","author":"Juhasz G.","year":"2009","unstructured":"Juhasz G.; Lazary J.; Chase D.; Pegg E.; Downey D.; Toth Z.G.; Stones K.; Platt H.; Mekli K.; Payton A.; Anderson I.M.; Deakin J.F.; Bagdy G.; Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett 2009,461(2),116-120","journal-title":"Neurosci Lett"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.expneurol.2010.03.029","volume":"224","author":"Greco R.","year":"2010","unstructured":"Greco R.; Gasperi V.; Maccarrone M.; Tassorelli C.; The endocannabinoid system and migraine. Exp Neurol 2010,224(1),85-91","journal-title":"Exp Neurol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1124\/jpet.103.059808","volume":"309","author":"Akerman S.","year":"2004","unstructured":"Akerman S.; Kaube H.; Goadsby P.J.; Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther a2004,309(1),56-63","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1129-2377-15-14","volume":"15","author":"Greco R.","year":"2014","unstructured":"Greco R.; Mangione A.S.; Sandrini G.; Nappi G.; Tassorelli C.; Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain 2014,15(14),14","journal-title":"J Headache Pain"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0333102413499646","volume":"34","author":"Ramadan N.M.","year":"2014","unstructured":"Ramadan N.M.; Glutamate and migraine: from Ikeda to the 21st century. Cephalalgia 2014,34(2),86-89","journal-title":"Cephalalgia"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF01046588","volume":"23","author":"Kai-Kai M.A.","year":"1991","unstructured":"Kai-Kai M.A.; Howe R.; Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat. Histochem J 1991,23(4),171-179","journal-title":"Histochem J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0304-3940(92)90339-9","volume":"141","author":"Tallaksen-Greene S.J.","year":"1992","unstructured":"Tallaksen-Greene S.J.; Young A.B.; Penney J.B.; Beitz A.J.; Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat Neurosci Lett 1992,141(1),79-83","journal-title":"Neurosci Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"Traynelis S.F.","year":"2010","unstructured":"Traynelis S.F.; Wollmuth L.P.; McBain C.J.; Menniti F.S.; Vance K.M.; Ogden K.K.; Hansen K.B.; Yuan H.; Myers S.J.; Dingledine R.; Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010,62(3),405-496","journal-title":"Pharmacol Rev"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2174\/138920111798357438","volume":"12","author":"Montana M.C.","year":"2011","unstructured":"Montana M.C.; Gereau R.W.; Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharm Biotechnol 2011,12(10),1681-1688","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1212\/01.wnl.0000306315.03021.2a","volume":"70","author":"Benarroch E.E.","year":"2008","unstructured":"Benarroch E.E.; Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease. Neurology 2008,70(12),964-968","journal-title":"Neurology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0166-2236(91)90022-M","volume":"14","author":"Garthwaite J.","year":"1991","unstructured":"Garthwaite J.; Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991,14(2),60-67","journal-title":"Trends Neurosci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"H1404","DOI":"10.1152\/ajpheart.00523.2001","volume":"282","author":"Domoki F.","year":"2002","unstructured":"Domoki F.; Perciaccante J.V.; Shimizu K.; Puskar M.; Busija D.W.; Bari F.; N-methyl-D-aspartate-induced vasodilation is mediated by endothelium-independent nitric oxide release in piglets. Am J Physiol Heart Circ Physiol 2002,282(4),H1404-H1409","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nn980","volume":"6","author":"Zonta M.","year":"2003","unstructured":"Zonta M.; Angulo M.C.; Gobbo S.; Rosengarten B.; Hossmann K.A.; Pozzan T.; Carmignoto G.; Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 2003,6(1),43-50","journal-title":"Nat Neurosci"},{"key":"ref=115","first-page":"197","volume":"339","author":"Sun W.","year":"2013","unstructured":"Sun W.; McConnell E.; Pare J-F.; Xu Q.; Chen M.; Peng W.; Lovatt D.; Han X.; Smith Y.; Nedergaard M.; Glutamate-Dependent Neuroglial Calcium signaling Differs Between Young and Adult Brain Science 2013,339,197"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrn1387","volume":"5","author":"Iadecola C.","year":"2004","unstructured":"Iadecola C.; Neurovascular regulation in the normal brain and in Alzheimer\u2019s disease. Nat Rev Neurosci 2004,5(5),347-360","journal-title":"Nat Rev Neurosci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/90507","volume":"4","author":"Parri H.R.","year":"2001","unstructured":"Parri H.R.; Gould T.M.; Crunelli V.; Spontaneous astrocytic Ca2+ oscillations in situ drive NMDAR-mediated neuronal excitation. Nat Neurosci 2001,4(8),803-812","journal-title":"Nat Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nn1623","volume":"9","author":"Takano T.","year":"2006","unstructured":"Takano T.; Tian G-F.; Peng W.; Lou N.; Libionka W.; Han X.; Nedergaard M.; Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006,9(2),260-267","journal-title":"Nat Neurosci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1526-4610.2008.01262.x","volume":"49","author":"Damodaram S.","year":"2009","unstructured":"Damodaram S.; Thalakoti S.; Freeman S.E.; Garrett F.G.; Durham P.L.; Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 2009,49(1),5-20","journal-title":"Headache"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/archneurpsyc.1941.02280200137007","volume":"46","author":"Lashley K.","year":"1941","unstructured":"Lashley K.; Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1941,46,331-339","journal-title":"Arch Neurol Psychiatry"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrneurol.2013.192","volume":"9","author":"Charles A.C.","year":"2013","unstructured":"Charles A.C.; Baca S.M.; Cortical spreading depression and migraine. Nat Rev Neurol 2013,9(11),637-644","journal-title":"Nat Rev Neurol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1046\/j.1468-2982.1997.1706652.x","volume":"17","author":"D\u2019Eufemia P.","year":"1997","unstructured":"D\u2019Eufemia P.; Finocchiaro R.; Lendvai D.; Celli M.; Viozzi L.; Troiani P.; Turri E.; Giardini O.; Erythrocyte and plasma levels of glutamate and aspartate in children affected by migraine. Cephalalgia 1997,17(6),652-657","journal-title":"Cephalalgia"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1177\/033310240102100704","volume":"21","author":"Lauritzen M.","year":"2001","unstructured":"Lauritzen M.; Cortical spreading depression in migraine. Cephalalgia 2001,21(7),757-760","journal-title":"Cephalalgia"},{"key":"ref=124","first-page":"H1095","volume":"266","author":"Colonna D.M.","year":"1994","unstructured":"Colonna D.M.; Meng W.; Deal D.D.; Busija D.W.; Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits. Am J Physiol 1994,266(3 Pt 2),H1095-H1102","journal-title":"Am J Physiol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1113\/jphysiol.1982.sp014220","volume":"327","author":"Hill R.G.","year":"1982","unstructured":"Hill R.G.; Salt T.E.; An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J Physiol 1982,327,65-78","journal-title":"J Physiol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0006-8993(00)02630-5","volume":"875","author":"Goadsby P.J.","year":"2000","unstructured":"Goadsby P.J.; Classey J.D.; Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res 2000,875(1-2),119-124","journal-title":"Brain Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0306-4522(98)00536-3","volume":"90","author":"Storer R.J.","year":"1999","unstructured":"Storer R.J.; Goadsby P.J.; Trigeminovascular nociceptive transmission involves N-methyl-Daspartate glutamate receptors. Neuroscience 1999,90(4),1371-1376","journal-title":"Neuroscience"},{"key":"ref=128","volume":"11","author":"Krusz J.C.","year":"2011","unstructured":"Krusz J.C.; Memantine for Migraine and Tension-Type Headache Prophylaxis. Pract Pain Manag 2011,11(1)","journal-title":"Pract Pain Manag"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-2982.2004.00723.x","volume":"24","author":"Sang C.N.","year":"2004","unstructured":"Sang C.N.; Ramadan N.M.; Wallihan R.G.; Chappell A.S.; Freitag F.G.; Smith T.R.; Silberstein S.D.; Johnson K.W.; Phebus L.A.; Bleakman D.; Ornstein P.L.; Arnold B.; Tepper S.J.; Vandenhende F.; LY293558, a novel AMPA\/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004,24(7),596-602","journal-title":"Cephalalgia"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/med\/9780199552764.003.0022","volume":"16","author":"Johnson K.W.","year":"2008","unstructured":"Johnson K.W.; Nisenbaum E.S.; Johnson M.P.; Dieckman D.K.; Clemens-Smith A.; Siuda E.R.; Dell C.P.; Dehlinger V.; Hudziak K.J.; Filla S.A.; Ornstein P.L.; Ramadan N.M.; Bleakman D.;  Innovative drug development for headache disorders; Olesen J, Ramadan N, Ed; Frontiers in headache research 2008,16,185-194","journal-title":"Innovative drug development for headache disorders; Olesen J, Ramadan N, Ed; Frontiers in headache research"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1468-2982.2009.01849.x","volume":"29","author":"Storer R.J.","year":"2009","unstructured":"Storer R.J.; Goadsby P.J.; N-methyl-D-aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. Cephalalgia 2009,29(Suppl. 1),135","journal-title":"Cephalalgia"},{"key":"ref=132","first-page":"960","volume":"288","author":"Taverna S.","year":"1999","unstructured":"Taverna S.; Sancini G.; Mantegazza M.; Franceschetti S.; Avanzini G.; Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999,288(3),960-968","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","volume":"41","author":"Zhang X.","year":"2000","unstructured":"Zhang X.; Velumian A.A.; Jones O.T.; Carlen P.L.; Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000,41(Suppl. 1),S52-S60","journal-title":"Epilepsia"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","volume":"42","author":"Herrero A.I.","year":"2002","unstructured":"Herrero A.I.; Del Olmo N.; Gonzalez-Escalada J.R.; Solis J.M.; Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance Neuropharmacology 2002,42(2),210-220","journal-title":"Neuropharmacology"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"Diener H.C.","year":"2007","unstructured":"Diener H.C.; Bussone G.; Van Oene J.C.; Lahaye M.; Schwalen S.; Goadsby P.J.; Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia TOPMAT-MIG-201(TOP-CHROME) Study Group2007,27(7),814-823","journal-title":"Cephalalgia"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40265-014-0262-0","volume":"74","author":"Chan K.","year":"2014","unstructured":"Chan K.; MaassenVanDenBrink A.; Glutamate receptor antagonists in the management of migraine. Drugs 2014,74(11),1165-1176","journal-title":"Drugs"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1468-2982.1997.1702109.x","volume":"17","author":"Steiner T.J.","year":"1997","unstructured":"Steiner T.J.; Findley L.J.; Yuen A.W.; Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997,17(2),109-112","journal-title":"Cephalalgia"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","volume":"43","author":"Dolly O.","year":"2003","unstructured":"Dolly O.; Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins Headache 2003,43(1),S16-24","journal-title":"Headache"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"Dodick D.W.","year":"2010","unstructured":"Dodick D.W.; Turkel C.C.; DeGryse R.E.; Aurora S.K.; Silberstein S.D.; Lipton R.B.; Diener H-C.; Brin M.F.; PREEMPT chronic migraine study group. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010,50(6),921-936","journal-title":"Headache"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2014.04.018","volume":"84","author":"S\u00e1nchez-Porras R.","year":"2014","unstructured":"S\u00e1nchez-Porras R.; Santos E.; Sch\u00f6ll M.; Stock C.; Zheng Z.; Schiebel P.; Orakcioglu B.; Unterberg A.W.; Sakowitz O.W.; The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. Neuropharmacology 2014,84,52-61","journal-title":"Neuropharmacology"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/WNL.0b013e3182824e66","volume":"80","author":"Afridi S.K.","year":"2013","unstructured":"Afridi S.K.; Giffin N.J.; Kaube H.; Goadsby P.J.; A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013,80(7),642-647","journal-title":"Neurology"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1212\/WNL.55.1.139","volume":"55","author":"Kaube H.","year":"2000","unstructured":"Kaube H.; Herzog J.; K\u00e4ufer T.; Dichgans M.; Diener H.C.; Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000,55(1),139-141","journal-title":"Neurology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/39807","volume":"389","author":"Caterina M.J.","year":"1997","unstructured":"Caterina M.J.; Schumacher M.A.; Tominaga M.; Rosen T.A.; Levine J.D.; Julius D.; The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997,389(6653),816-824","journal-title":"Nature"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00424-005-1423-5","volume":"451","author":"Planells-Cases R.","year":"2005","unstructured":"Planells-Cases R.; Garc\u00eca-Sanz N.; Morenilla-Palao C.; Ferrer- Montiel A.; Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia. Pflugers Arch 2005,451(1),151-159","journal-title":"Pflugers Arch"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0968-0004(99)01426-7","volume":"24","author":"Sedgwick S.G.","year":"1999","unstructured":"Sedgwick S.G.; Smerdon S.J.; The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 1999,24(8),311-316","journal-title":"Trends Biochem Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1526-4610.2011.02053.x","volume":"52","author":"Evans M.S.","year":"2012","unstructured":"Evans M.S.; Cheng X.; Jeffry J.A.; Disney K.E.; Premkumar L.S.; Sumatriptan inhibits TRPV1 channels in trigeminal neurons. Headache 2012,52(5),773-784","journal-title":"Headache"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/0306-4522(88)90064-4","volume":"24","author":"Holzer P.","year":"1988","unstructured":"Holzer P.; Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988,24(3),739-768","journal-title":"Neuroscience"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1124\/jpet.102.046250","volume":"304","author":"Rashid M.H.","year":"2003","unstructured":"Rashid M.H.; Inoue M.; Kondo S.; Kawashima T.; Bakoshi S.; Ueda H.; Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther 2003,304(3),940-948","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/138161208783330754","volume":"14","author":"Gunthorpe M.J.","year":"2008","unstructured":"Gunthorpe M.J.; Szallasi A.; Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008,14(1),32-41","journal-title":"Curr Pharm Des"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajmg.b.32007","volume":"159","author":"Carreno O.","year":"2012","unstructured":"Carreno O.; Corominas R.; Fernandez-Morales J.; Camina M.; Sobrido M-J.; Fernandez-Fernandez J.M.; Pozo-Rosich P.; Cormand B.; Macaya A.; SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population A J MedGenet Part B 2012,159,94-103","journal-title":"A J MedGenet Part B"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0166-2236(94)90149-X","volume":"17","author":"Bevan S.","year":"1994","unstructured":"Bevan S.; Geppetti P.; Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci 1994,17(12),509-512","journal-title":"Trends Neurosci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0896-6273(00)80564-4","volume":"21","author":"Tominaga M.","year":"1998","unstructured":"Tominaga M.; Caterina M.J.; Malmberg A.B.; Rosen T.A.; Gilbert H.; Skinner K.; Raumann B.E.; Basbaum A.I.; Julius D.; Julius D.; The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998,21(3),531-543","journal-title":"Neuron"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/22761","volume":"400","author":"Zygmunt P.M.","year":"1999","unstructured":"Zygmunt P.M.; Petersson J.; Andersson D.A.; Chuang H.; S\u00f8rg\u00e5rd M.; Di Marzo V.; Julius D.; H\u00f6gest\u00e4tt E.D.; Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999,400(6743),452-457","journal-title":"Nature"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1073\/pnas.97.11.6155","volume":"97","author":"Hwang S.W.","year":"2000","unstructured":"Hwang S.W.; Cho H.; Kwak J.; Lee S.Y.; Kang C-J.; Jung J.; Cho S.; Min K.H.; Suh Y-G.; Kim D.; Oh U.; Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000,97(11),6155-6160","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1038\/sj.emboj.7600784","volume":"24","author":"van der Stelt M.","year":"2005","unstructured":"van der Stelt M.; Trevisani M.; Vellani V.; De Petrocellis L.; Schiano Moriello A.; Campi B.; McNaughton P.; Geppetti P.; Di Marzo V.; Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J 2005,24(17),3026-3037","journal-title":"EMBO J"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0896-6273(00)80813-2","volume":"23","author":"Cesare P.","year":"1999","unstructured":"Cesare P.; Dekker L.V.; Sardini A.; Parker P.J.; McNaughton P.A.; Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999,23(3),617-624","journal-title":"Neuron"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/35082088","volume":"411","author":"Chuang H-H.","year":"2001","unstructured":"Chuang H-H.; Prescott E.D.; Kong H.; Shields S.; Jordt S-E.; Basbaum A.I.; Chao M.V.; Julius D.; Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001,411(6840),957-962","journal-title":"Nature"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.1073\/pnas.122196999","volume":"99","author":"Huang S.M.","year":"2002","unstructured":"Huang S.M.; Bisogno T.; Trevisani M.; Al-Hayani A.; De Petrocellis L.; Fezza F.; Tognetto M.; Petros T.J.; Krey J.F.; Chu C.J.; Miller J.D.; Davies S.N.; Geppetti P.; Walker J.M.; Di Marzo V.; An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002,99(12),8400-8405","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1744-8069-1-3","volume":"1","author":"Moriyama T.","year":"2005","unstructured":"Moriyama T.; Higashi T.; Togashi K.; Iida T.; Segi E.; Sugimoto Y.; Tominaga T.; Narumiya S.; Tominaga M.; Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005,1,3-9","journal-title":"Mol Pain"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1523\/JNEUROSCI.5403-05.2006","volume":"26","author":"Negri L.","year":"2006","unstructured":"Negri L.; Lattanzi R.; Giannini E.; Colucci M.; Margheriti F.; Melchiorri P.; Vellani V.; Tian H.; De Felice M.; Porreca F.; Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. J Neurosci 2006,26(25),6716-6727","journal-title":"J Neurosci"},{"key":"ref=161","first-page":"143","volume":"43","author":"Holzer P.","year":"1991","unstructured":"Holzer P.; Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991,43(2),143-201","journal-title":"Pharmacol Rev"},{"key":"ref=162","first-page":"159","volume":"51","author":"Szallasi A.","year":"1999","unstructured":"Szallasi A.; Blumberg P.M.; Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999,51(2),159-212","journal-title":"Pharmacol Rev"},{"key":"ref=163","author":"Geppetti P.","year":"1996","unstructured":"Geppetti P.; Holzer P.;  Neurogenic inflammation 1996","journal-title":"Neurogenic inflammation"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1523\/JNEUROSCI.18-16-06081.1998","volume":"18","author":"Lopshire J.C.","year":"1998","unstructured":"Lopshire J.C.; Nicol G.D.; The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies. J Neurosci 1998,18(16),6081-6092","journal-title":"J Neurosci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1046\/j.1460-9568.2000.00218.x","volume":"12","author":"Smith J.A.M.","year":"2000","unstructured":"Smith J.A.M.; Davis C.L.; Burgess G.M.; Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur J Neurosci 2000,12(9),3250-3258","journal-title":"Eur J Neurosci"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1152\/jn.00748.2002","volume":"89","author":"Gu Q.","year":"2003","unstructured":"Gu Q.; Kwong K.; Lee L-Y.; Ca2+ transient evoked by chemical stimulation is enhanced by PGE2 in vagal sensory neurons: role of cAMP\/PKA signaling pathway. J Neurophysiol 2003,89(4),1985-1993","journal-title":"J Neurophysiol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-2982.2007.01448.x","volume":"28","author":"Nicoletti P.","year":"2008","unstructured":"Nicoletti P.; Trevisani M.; Manconi M.; Gatti R.; De Siena G.; Zagli G.; Benemei S.; Capone J.A.; Geppetti P.; Pini L.A.; Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 2008,28(1),9-17","journal-title":"Cephalalgia"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2006.04.046","volume":"540","author":"Lappin S.C.","year":"2006","unstructured":"Lappin S.C.; Randall A.D.; Gunthorpe M.J.; Morisset V.; TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol 2006,540(1-3),73-81","journal-title":"Eur J Pharmacol"},{"key":"ref=169","first-page":"153","author":"Meents J.E.","year":"2010","unstructured":"Meents J.E.; Neeb L.; Reuter U.;  TRPV1 in migraine pathophysiology 2010,153-159","journal-title":"TRPV1 in migraine pathophysiology"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-015-0539-z","volume":"16","author":"Meents J.E.","year":"2015","unstructured":"Meents J.E.; Hoffmann J.; Chaplan S.R.; Neeb L.; Schuh-Hofer S.; Wickenden A.; Reuter U.; Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. J Headache Pain 2015,16,57","journal-title":"J Headache Pain"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1741-7015-7-71","volume":"7","author":"Sprenger T.","year":"2009","unstructured":"Sprenger T.; Goadsby P.J.; Migraine pathogenesis and state of pharmacological treatment options. BMC Med 2009,7,71","journal-title":"BMC Med"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/sj.bjp.0705486","volume":"140","author":"Akerman S.","year":"2003","unstructured":"Akerman S.; Kaube H.; Goadsby P.J.; Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 2003,140(4),718-724","journal-title":"Br J Pharmacol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/S1090-3801(09)60705-9","volume":"13","author":"Chizh B.","year":"2009","unstructured":"Chizh B.; Palmer J.; Lai R.; Guillard F.; Bullman J.; Baines A.; Napolitano A.; Appleby A.; A randomised, two-period cross-over study to investigate the efficacy of the TRPV1 antagonist SB-705498 in acute migraine. Poster Sessions. Eur J Pain 2009,13,S55-S285","journal-title":"Eur J Pain"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/jemt.1085","volume":"53","author":"Artico M.","year":"2001","unstructured":"Artico M.; Cavallotti C.; Catecholaminergic and acetylcholine esterase containing nerves of cranial and spinal dura mater in humans and rodents. Microsc Res Tech 2001,53(3),212-220","journal-title":"Microsc Res Tech"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.brainresrev.2004.11.006","volume":"49","author":"Theoharides T.C.","year":"2005","unstructured":"Theoharides T.C.; Donelan J.; Kandere-Grzybowska K.; Konstantinidou A.; The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 2005,49(1),65-76","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature01324","volume":"420","author":"Benoist C.","year":"2002","unstructured":"Benoist C.; Mathis D.; Mast cells in autoimmune disease. Nature 2002,420(6917),875-878","journal-title":"Nature"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/S1357-2725(03)00208-5","volume":"35","author":"Puxeddu I.","year":"2003","unstructured":"Puxeddu I.; Piliponsky A.M.; Bachelet I.; Levi-Schaffer F.; Mast cells in allergy and beyond. Int J Biochem Cell Biol 2003,35(12),1601-1607","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMcibr023206","volume":"348","author":"Woolley D.E.","year":"2003","unstructured":"Woolley D.E.; The mast cell in inflammatory arthritis. N Engl J Med 2003,348(17),1709-1711","journal-title":"N Engl J Med"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1034\/j.1600-065X.2000.917305.x","volume":"173","author":"Mekori Y.A.","year":"2000","unstructured":"Mekori Y.A.; Metcalfe D.D.; Mast cells in innate immunity. Immunol Rev 2000,173,131-140","journal-title":"Immunol Rev"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1152\/physrev.1997.77.4.1033","volume":"77","author":"Metcalfe D.D.","year":"1997","unstructured":"Metcalfe D.D.; Baram D.; Mekori Y.A.; Mast cells. Physiol Rev 1997,77(4),1033-1079","journal-title":"Physiol Rev"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ddr.20208","volume":"68","author":"Levy D.","year":"2007","unstructured":"Levy D.; Meningeal mast cells, inflammation and migraine pain. Drug Dev Res 2007,68,412-418","journal-title":"Drug Dev Res"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/j.1471-4159.1984.tb05416.x","volume":"43","author":"Orr E.L.","year":"1984","unstructured":"Orr E.L.; Dural mast cells: source of contaminating histamine in analyses of mouse brain histamine levels. J Neurochem 1984,43(5),1497-1499","journal-title":"J Neurochem"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/BF01252276","volume":"20","author":"Dimlich R.V.W.","year":"1991","unstructured":"Dimlich R.V.W.; Keller J.T.; Strauss T.A.; Fritts M.J.; Linear arrays of homogeneous mast cells in the dura mater of the rat. J Neurocytol 1991,20(6),485-503","journal-title":"J Neurocytol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbrc.2014.07.124","volume":"451","author":"Wong G.W.","year":"2014","unstructured":"Wong G.W.; Zhuo L.; Kimata K.; Lam B.K.; Satoh N.; Stevens R.L.; Ancient origin of mast cells. Biochem Biophys Res Commun 2014,451(2),314-318","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1476-5381.1997.tb06811.x","volume":"120","author":"Ash A.S.","year":"1997","unstructured":"Ash A.S.; Schild H.O.; Receptors mediating some actions of histamine. 1966. Br J Pharmacol 1997,120(4)(Suppl.),302-314","journal-title":"Br J Pharmacol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1124\/mol.55.6.1101","volume":"55","author":"Lovenberg T.W.","year":"1999","unstructured":"Lovenberg T.W.; Roland B.L.; Wilson S.J.; Jiang X.; Pyati J.; Huvar A.; Jackson M.R.; Erlander M.G.; Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999,55(6),1101-1107","journal-title":"Mol Pharmacol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"36781","DOI":"10.1074\/jbc.M006480200","volume":"275","author":"Oda T.","year":"2000","unstructured":"Oda T.; Morikawa N.; Saito Y.; Masuho Y.; Matsumoto S.; Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000,275(47),36781-36786","journal-title":"J Biol Chem"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00202867","volume":"94","author":"Le Coniat M.","year":"1994","unstructured":"Le Coniat M.; Traiffort E.; Ruat M.; Arrang J.M.; Berger R.; Chromosomal localization of the human histamine H1-receptor gene. Hum Genet 1994,94(2),186-188","journal-title":"Hum Genet"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1073\/pnas.88.2.429","volume":"88","author":"Gantz I.","year":"1991","unstructured":"Gantz I.; Sch\u00e4ffer M.; DelValle J.; Logsdon C.; Campbell V.; Uhler M.; Yamada T.; Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci USA 1991,88(2),429-433","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1006\/bbrc.2000.4008","volume":"279","author":"Nakamura T.","year":"2000","unstructured":"Nakamura T.; Itadani H.; Hidaka Y.; Ohta M.; Tanaka K.; Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000,279(2),615-620","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1212\/WNL.25.7.681","volume":"25","author":"Saxena P.R.","year":"1975","unstructured":"Saxena P.R.; The significance of histamine H1 and H2 receptors on the carotid vascular bed in the dog. Neurology 1975,25(7),681-687","journal-title":"Neurology"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/jcbfm.1981.49","volume":"1","author":"Gross P.M.","year":"1981","unstructured":"Gross P.M.; Histamine H1- and H2-receptors are differentially and spatially distributed in cerebral vessels. J Cereb Blood Flow Metab 1981,1(4),441-446","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/302832a0","volume":"302","author":"Arrang J.M.","year":"1983","unstructured":"Arrang J.M.; Garbarg M.; Schwartz J.C.; Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983,302(5911),832-837","journal-title":"Nature"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0304-3959(88)90012-7","volume":"8","author":"Krabbe A.A.","year":"1980","unstructured":"Krabbe A.A.; Olesen J.; Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain 1980,8(2),253-259","journal-title":"Pain"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1152\/ajplegacy.1971.221.6.1629","volume":"221","author":"Oldendorf W.H.","year":"1971","unstructured":"Oldendorf W.H.; Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 1971,221(6),1629-1639","journal-title":"Am J Physiol"},{"key":"ref=196","first-page":"H311","volume":"258","author":"Toda N.","year":"1990","unstructured":"Toda N.; Mechanism underlying responses to histamine of isolated monkey and human cerebral arteries. Am J Physiol 1990,258(2 Pt 2),H311-H317","journal-title":"Am J Physiol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.bjp.0701097","volume":"121","author":"Jansen-Olesen I.","year":"1997","unstructured":"Jansen-Olesen I.; Ottosson A.; Cantera L.; Strunk S.; Lassen L.H.; Olesen J.; Mortensen A.; Engel U.; Edvinsson L.; Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H1- and H2-receptors by RT-PCR. Br J Pharmacol 1997,121(1),41-48","journal-title":"Br J Pharmacol"},{"key":"ref=198","author":"Tizard I.R.","year":"1995","unstructured":"Tizard I.R.;  Immunology: An Introduction Fourth international edition 1995","journal-title":"Immunology: An Introduction Fourth international edition"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0009-9236(95)90074-8","volume":"58","author":"Bedarida G.","year":"1995","unstructured":"Bedarida G.; Bushell E.; Blaschke T.F.; Hoffman B.B.; H1- and H2-histamine receptor-mediated vasodilation varies with aging in humans. Clin Pharmacol Ther 1995,58(1),73-80","journal-title":"Clin Pharmacol Ther"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1468-2982.1997.1703175.x","volume":"17","author":"Schmetterer L.","year":"1997","unstructured":"Schmetterer L.; Wolzt M.; Graselli U.; Findl O.; Strenn K.; Simak S.; Kastner J.; Eichler H.G.; Singer E.A.; Nitric oxide synthase inhibition in the histamine headache model. Cephalalgia 1997,17(3),175-182","journal-title":"Cephalalgia"},{"key":"ref=201","first-page":"739","volume":"218","author":"Ignarro L.J.","year":"1981","unstructured":"Ignarro L.J.; Lippton H.; Edwards J.C.; Baricos W.H.; Hyman A.L.; Kadowitz P.J.; Gruetter C.A.; Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981,218(3),739-749","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1046\/j.1468-2982.2003.00586.x","volume":"23","author":"Lassen L.H.","year":"2003","unstructured":"Lassen L.H.; Christiansen I.; Iversen H.K.; Jansen-Olesen I.; Olesen J.; The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003,23(9),877-886","journal-title":"Cephalalgia"},{"key":"ref=203","first-page":"191","year":"2009","unstructured":"Dux. M.; Messlinger, K. Neurogenic Vascular Responses in the Dura Mater and their Relevance for the Pathophysiology of Headaches Neuro Immune Biology 2009,191-209","journal-title":"Neuro Immune Biology"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/00005392-199503000-00021","volume":"153","author":"Theoharides T.C.","year":"1995","unstructured":"Theoharides T.C.; Sant G.R.; el-Mansoury M.; Letourneau R.; Ucci A.A.; Meares E.M.; Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J Urol 1995,153(3 Pt 1),629-636","journal-title":"J Urol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","volume":"36","author":"Couch J.R.","year":"1979","unstructured":"Couch J.R.; Hassanein R.S.; Amitriptyline in migraine prophylaxis. Arch Neurol 1979,36(11),695-699","journal-title":"Arch Neurol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","volume":"107","author":"Bulut S.","year":"2004","unstructured":"Bulut S.; Berilgen M.S.; Baran A.; Tekatas A.; Atmaca M.; Mungen B.; Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004,107(1),44-48","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0196-0644(98)70126-X","volume":"32","author":"Carleton S.C.","year":"1998","unstructured":"Carleton S.C.; Shesser R.F.; Pietrzak M.P.; Chudnofsky C.R.; Starkman S.; Morris D.L.; Johnson G.; Rhee K.J.; Barton C.W.; Chelly J.E.; Rosenberg J.; Van Valen M.K.; Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 1998,32(2),129-138","journal-title":"Ann Emerg Med"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185266\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:57:04Z","timestamp":1746572224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185266\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":207,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467213999200824124532","relation":{},"ISSN":["1874-4672"],"issn-type":[{"type":"print","value":"1874-4672"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}